Current aspects in hemoglobin A1c detection: A review by Ang, S.H. et al.
Post-print version
ClinicaChimicaActa439(2015)202–211Invited critical reviewCurrent aspects in hemoglobin A1c detection: A reviewShu Hwang Ang a, M. Thevarajah b, Yatimah Alias a, Sook Mei Khor a,⁎
a Department of Chemistry, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia
b Department of Pathology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia⁎ Corresponding author. Tel.: +60 3 79677022x2520; f
E-mail address: naomikhor@um.edu.my (S.M. Khor).
http://dx.doi.org/10.1016/j.cca.2014.10.019a b s t r a c ta r t i c l e i n f oArticle history:
Received 22 July 2014
Received in revised form 9 October 2014
Accepted 11 October 2014
Available online 22 October 2014
Keywords:
Type 2 diabetes mellitus
Hemoglobin A1c tests
IFCC (International Federation of Clinical
Chemistry and Laboratory Medicine)
NGSP (National Glycohemoglobin
Standardization Program)
POC technology
BiosensorsType 2 diabetes mellitus (T2DM) is a pressing health issue that threatens global health and the productivity of
populations worldwide. Despite its long-recognized role in diabetes management, glycated hemoglobin
(HbA1c) only received WHO endorsement as a T2DM diagnostic tool in 2011. Although conventional plasma-
speciﬁc tests have long been utilized to diagnose T2DM, the public should be informed that plasma-speciﬁc
tests are notmarkedly better thanHbA1c tests, particularly in terms of variability and convenience for diagnosing
diabetes. In the midst of the debates associated with establishing HbA1c as the preeminent diabetes diagnostic
tool, unceasing efforts to standardize HbA1c tests have played an integral part in achieving more efﬁcient com-
munication from laboratory to clinical practice and thus better diabetes care. This review discusses the current
status of HbA1c tests in the diagnosis, prevention, treatment andmanagement of T2DMacross the globe, focusing
on increasing the recognition of glycated hemoglobin variants with effective utilization of different HbA1c
methods, updating the current status of HbA1c standardization programs, tapping into the potential of POC
analyzers to establish a cost-effective HbA1c test for diabetes care, and inspiring the advancement of HbA1c
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Type 2 diabetes mellitus (T2DM) is a global epidemic health issue.
Approximately 439 million adults (7.7% of the world's adult populationax: +60 3 79674195.aged 20–79 years) are estimated to be afﬂicted with diabetes by 2030
[1]. As a consequence of population growth, longer life expectancy,
and lifestyle changes, the estimated 54% increase in T2DM incidence
worldwide by 2030 is concerning [1]. Although the spreading of the
chronic disease itself is worrisome, the medical complications and
socioeconomic impacts associated with diabetes are as fearful as the
disease itself. Individualswith diabetes are at increased risk of developing
microvascular (mainly retinopathy, nephropathy, and neuropathy) and
macrovascular (especially stroke and coronary artery) diseases. Acute
episodes such as diabetic ketoacidosis, hyperosmolar coma, and severe
hypoglycemia can lead to morbidity and mortality [2], which could be-
come a socioeconomic burden.
Diabetes is a metabolic disorder that consists of multiple etiologies
characterized by chronic hyperglycemiawith disturbances in the carbo-
hydrate, fat and proteinmetabolism resulting from defects in insulin se-
cretion, insulin action, or both [3]. The diagnosis of diabetes can be very
complicated, due to variations in diabetic symptoms. Some diabetic
patients can be asymptomatic, whereas others have evident symptoms.
In general, the diagnostic tests for type 2 diabetes mellitus can be
grouped into two distinct categories, namely plasma-speciﬁc tests and
the whole blood glycated hemoglobin (HbA1c) test. The HbA1c test
has been the subject of multiple controversies, typically focusing on
the precision and accuracy associated with different commercialized
detection methods. Nonetheless, the role of glycated hemoglobin as a
distinctive biomarker for type 2 diabetes mellitus is undeniable.
Hence, a biological understanding of the role of HbA1c is necessary be-
fore a discussion of the detection methods.
2. Biological challenges encountered in HbA1c tests: glycated
hemoglobin and its variants
Some biological problems can interfere with HbA1c assays, particu-
larly when glycated hemoglobin variants are present, when the red
blood cells' turnover rate is affected by morbidities, or when the
glycation rate is inﬂuenced by genetic and dietary factors (for a detailed
description please refer to Hare et al. [4]). In general, a healthy individ-
uals' hemoglobin can be categorized into the following three groups:
HbA (adult hemoglobin, 97%), HbA2 (2.5%) and HbF (fetal hemoglobin,
0.5%) [5]. The majority of HbA is not glycated (approximately 94%), and
approximately 6% of HbA can be categorized as glycated hemoglobin
[5]. In other words, as the main glycated component (HbA1a and
HbA1b together contribute approximately 1%), HbA1c composes ap-
proximately 5% of the total hemoglobin in a healthy individual [6]
(Fig. 1).
In general, glycation occurs spontaneously and non-enzymatically
when glucose reacts with the amine groups in proteins to form a stable
ketoamine, the Amadori compound (refer to Fig. 2). Further oxidation
and rearrangement result in more reactive species, also known as
advanced glycation end-products (AGEs), which are thought to be in-
volved in diabetic complications [7]. Of the glycated protein species,
the glycated hemoglobin, HbA1c, was chosen to gauge glycemic control
in diabetic patients due to the stability of its Amadori form.HbA1c formsFig. 1.Hemoglobin and its variants. Hemoglobin can exist inmainly three forms in healthy adult
inHbForHbA2 forms.HbA,HbF, andHbA2 are uniquewith the different subunits. HbAhas twoα
is consist of twoα and δ subunits (ααδδ). On the other hand, hemoglobin variants exist at the ex
ﬁgure are the general ones; there is a span of variants that could be silent while interferingwith
HbA0 species; majority of the glycated HbA1 species is the HbA1c fraction [5,12]. Glycation ca
substitution.when glucose attaches speciﬁcally to the N-terminal valine of the β
subunit of hemoglobin. However, only 60% of glucose is attached to
N-terminal β-chain valines. Glycation can also occurs on the lysine
side chains either on the α or β chains [8,9].
The glycated hemoglobin variants exist due to congenital disorders
of globin chain synthesis, called “hemoglobinopathies”. Although
some variants can directly interfere with the HbA1c test, some variants
interfere by causing premature turnover of red blood cells. In cases
where an individual is heterogeneous, the individualwill be asymptom-
atic and have normal red cell survival. For example, HbS homozygosity
leads to sickle cell anemia, which involves premature turnover of red
blood cells, whereas thosewho are heterozygous for the sickle cell allele
are asymptomatic [10]. Because variants can lead to over or underesti-
mation of glycated hemoglobin, it is very important to perform screen-
ing for hemoglobinopathies before HbA1c deﬁnitive tests, particularly
for those of Mediterranean, African or Southeast Asian heritage, who
exhibit a higher prevalence of hemoglobinopathies [11].
2.1. Plasma-speciﬁc tests versus HbA1c test for diagnosis
There are different tests for the measurement of glucose levels. Be-
cause tests employed in clinical settings depend on clinical decisions,
variation in diabetes diagnostic tests is common across different health
systems. Conventionally, the fasting plasma glucose (FPG), 2-hour post
glucose loading with oral tolerance test (OGTT) and random plasma
glucose (RPG) are categorized as plasma-speciﬁc tests, in which the
plasma glucose is measured.
The most widely accepted type 2 diabetes mellitus diagnostic tests
are the fasting plasma glucose (FPG) and the 2-hour plasma glucose
by the oral glucose tolerance test (OGTT). Because not all patients
show symptoms of diabetes, the use of a random plasma glucose test,
which involves apparent symptoms, such as unexplained weight loss,
increased thirst, and a high level of glycosuria, is not practical for the
diagnosis of diabetes in all cases [13]. While both FPG (diagnostic of
diabetes at plasma glucose level ≥126 mg/dL or 7.0 mmol/L [14]) and
OGTT (diagnostic of diabetes at plasma glucose level ≥200 mg/dL or
11.1 mmol/L [14]) are commonly used diagnostic tests, the associated
advantages, such as low cost and the popularity of automated laborato-
ry machines, make FPG the preferred test. Even so, FPG is commonly af-
fected by biological variations, preanalytical variations such as extended
incubation time of the blood samples (glycolysis can occur), and analyt-
ical variations (inwhich the serum insteadof plasmaglucose concentra-
tion is measured) [15]. While analytical variations can occur when
serum instead of plasma is used for the glucose measurement, ﬁndings
have concluded that the glucose measurement in serum and plasma dos, HbA contributes to around 97% of thewhole pool, while the rest of hemoglobin can exist
andβ subunits (ααββ), whileHbF ismadeupof twoα andγ subunits (ααγγ), andHbA2
pense of single amino acid substitution at the beta chain of HbA. The variants shown in the
HbA1c tests (not shown in ﬁgure). Glycation occursmostly on HbA1 species and some on
n also occur on the variants as long as the glucose-binding moiety is not affected by the
Fig. 2. Formation of glycated hemoglobin. Along the lifespan of a red blood cell (120 days), the hemoglobin is constantly in contact with glucose in the blood stream. Glucose reacts
nonenzymatically with the hemoglobin amine group, and when it speciﬁcally binds to valine of beta chain of hemoglobin, it undergoes the intermediate stage (Schiff base) and becomes
stable Amodori product, which is known as HbA1c (the glycated hemoglobin). There arewhole series ofmembrane proteins that undergo the same glycation reaction in the blood stream,
most of them undergo further oxidation and rearrangement to become amore reactive species, advance glycation end-products (AGEs) (not shown in the ﬁgure) that are perceived to be
responsible for the long term diabetes complications.not differ substantially [16]. However, clinical organizations do not
recommend the measurement of serum glucose for the diagnosis of
diabetes [16].
Although the OGTT has long been established as one of the diagnostic
modalities for diabetes, comparedwith FPG, it is less favored as a plasma
glucose test in clinical settings [15]. In fact, theWHOdiscouraged the use
of the OGTT for the diagnosis of diabetes due to its inconvenience, high
cost, and poor reproducibility [17]. Due to its principle of testing the
efﬁciency of carbohydrate metabolism, patients who undergo the OGTT
need intensive preparation before the test. In addition to requiring a
10- to 16-hour fast, the test has to be performed in the early morning
between 7 and 9 am, which can be very tedious for both patients and
clinicians [15]. As previously mentioned, the casual plasma glucose
(random plasma glucose, RPG) indicates diagnosis of type 2 diabetes
when the plasma glucose is≥200 mg/dL (11.1 mmol/L) in combination
with apparent classical diabetes symptoms. Although the random
plasma glucose test can be carried out anytime, it is very insensitive as
a screening tool for diabetes [18]. To maximize the test's sensitivity, a
3-year epidemiological study suggested that the cutoff should be adjust-
ed to RPG ≥130 mg/dL (7.2 mmol/L) to provide good yield and mini-
mize false positives [19]. While some argue that casual plasma glucose
is very convenient to avoid a long fast, standardized HbA1c tests offer a
better alternative that remains convenient while offsetting the sensitivi-
ty issues associated with RPG.
Despite being considered the preferred plasma-speciﬁc T2DM diag-
nostic test, the biological variability of FPG is 14%, indicating that the
test is neither perfectly stable nor free of laboratory variability [20].
Additionally, the comparison of both the FPG and HbA1c tests with
the OGTT revealed no evidence that FPG is superior to the HbA1c test
[21]. Because there is no speciﬁc evidence to endorse the superiority
of the FPG test, thewide implementation of theHbA1c test as a diagnos-
tic tool for type 2 diabetes should be considered.2.2. Current trends in glycated/glycosylated hemoglobin (HbA1c) tests for
diagnosing diabetes
Given the ease of testingwithout prolonged patient preparation, low
intra-individual biological variability (stable in the presence of sudden
glycemic variations, thus providing a better reﬂection of the plasma
glycemic status over the past 2–3 months), and greater reproducibility
[22], the HbA1c test is rapidly replacing the conventional approach for
diagnosing diabetes. This shift has a huge impact on the public health
sector, which is accustomed to the conventional plasma-speciﬁc tests.In 2010, the ADA (American Diabetes Association) endorsed HbA1c
as a diagnostic criterion for diabetes [23]. The ADA selected a result of
6.5% as the diagnostic value for type 2 diabetesmellitus (T2DM), gauged
by the development of diabetic retinopathy, which increases steeply at
≥6.5% [23]. In 2011, the HbA1c test was endorsed by the WHO as a di-
abetes diagnostic test, provided that the measurements are performed
by standardized HbA1c tests that passed the stringent quality assurance
tests [24]. As such, HbA1c has ofﬁcially become a diabetes diagnostic
tool.
Although its role as a diabetes biomarker is undisputable, HbA1c has
yet to receive the designation of “the” diabetes diagnosis tools across the
globe due to initial difﬁculties in standardizing HbA1c assays. For exam-
ple, the ChinaGuideline regarding type 2 diabetes in 2010did not recom-
mend the HbA1c test for the diagnosis of diabetes due to inconclusive
results in the Chinese population and the lack of a standardized HbA1c
measurement nationwide [22]. More longitudinal epidemiological stud-
ies have to be conducted to identify the demographic and ethnic factors
that may potentially contribute to complications in using HbA1c in type
2 diabetes diagnosis. Even after the role of HbA1c was recognized, argu-
ments regarding the ﬂuctuations in HbA1c levels due to genetic and bio-
logical variations, coexisting medical complications, assay interference
and high costs associated with its wide application in health systems
have continued [25]. Instead of debating the plausibility of implementing
HbA1c as a diagnostic tool, it ismore realistic to resolve the problems and
adjust the diagnostic cutoffs according to demographic, anthropometric,
or laboratory measurements to maintain consistency without losing the
sensitivity of the HbA1c tests.
Studies have been conducted to mitigate the disputes by combining
the results of the HbA1c test with the preferred plasma-speciﬁc test,
namely the fasting plasma glucose test (FPG). An eight-year longitudi-
nal prospective study of the Chinese population concluded that the
HbA1c test was better at predicting the incidence of diabetes than the
fasting plasma glucose test in clinical practice, the study suggested
that the combination of FPG, HbA1c and WC (waist circumference) be
used to accurately diagnose diabetes [26]. Additionally, a study conduct-
ed in Tokyo found that the combination of FPG at 6.1–6.9 mmol/L and
6.0–6.4% HbA1c levels yielded a prediction of an absolute progression
to type 2 diabetes over the course of ﬁve years [27], indicating that the
combination of plasma and HbA1c tests can be used to improve the
diagnosis efﬁciency.
In short, HbA1c tests have huge potential to aid the diagnosis and
screening of type 2 diabetes. Although therewere some obstacles initially,
intensive efforts to standardize HbA1c methods are slowly gaining trac-
tion in clinical laboratories across the globe. As such, better adaptation
of the HbA1c test as a diagnostic tool is to be expected when all HbA1c
methods are standardized against the IFCC (International Federation of
Clinical Chemistry) reference methods.
3. Towards standardization of HbA1c tests
Ever since the Diabetes Control and Complications Trial (DCCT) [28]
and the UK Prospective Diabetes Study (UKPDS) [29] showed a good re-
lationship between glycemic control and reduced outcome risks, the
precise measurement of HbA1c (long used as a glycemic management
test) was highly sought after. Although HbA1c methods ﬂourished, the
lack of a primary reference method led to inconsistent interpretations
of the HbA1c level. In the absence of an international standard method
to measure HbA1c, few countries have initiated national standardiza-
tion programs to set a reference method. For example, Mono-S ion-
exchange chromatography was employed as the standard method in
Sweden, whereas the Japan Diabetes Society (JDS) used two calibrators
with JDS-assigned values [30]. In an effort to standardize HbA1c tests,
theNGSP (National Glycohemoglobin Standardization Program) started
out as the subcommittee of the AACC (American Association for Clinical
Chemistry) in 1996, with a network of reference laboratories calibrated
against the DCCT reference values [30]. Secondary Reference Laborato-
ries (SRLs) under the NGSP work speciﬁcally with manufacturers to
standardize HbA1c kits or methods and compare data directly with
the DCCT results for method certiﬁcation [31]. The IFCC (International
Federation of Clinical Chemistry and Laboratory Medicine) Working
Group, whose purpose is to perfect reference methods for higher-level
calibration systems, established a higher-order reference method in
2001 (refer to Section 4 for a discussion of the IFCC reference method).
Although both the IFCC and NGSP have established distinctive laborato-
ry networks, continuous monitoring within and between IFCC and
NGSP laboratory networks allows harmonization of HbA1c results
worldwide [32]. To monitor the effectiveness of the NGSP in harmoniz-
ing the HbA1c results, it is evaluated by the College of American Pathol-
ogists (CAP) twice per annum [31]. Through the constant assessment
and scaling up of the certiﬁcation criteria, the CVs (coefﬁcient variants)
within and between laboratories have decreased, justifying the routine
use of HbA1c tests to aid in the clinical decisions on diabetes manage-
ment and diagnosis [32].
Because the IFCC and NGSP utilize different reference methods for
standardizing the HbA1c methods (the NGSP network reports in
%HbA1c, and the IFCC network reports inmmol HbA1c/mol Hb), the ab-
solute numbers reported are different between the two groups. The
IFCC reference system's measurements are typically 1.5–2.0% units
lower than the NGSP values [33], possibly due to the higher speciﬁcity
of IFCC methods. Although they are more accurate, IFCC methods are
more time consuming and comparatively higher in cost and are not
meant for routine clinical usage. Therefore, the NGSP values prevail as
the better assessment tool for diabetes diagnosis and management
(due to the traceability to UKPDS and DCCT), and most clinical settings
utilize NGSP units to report HbA1c values. To avoid confusion, a master
equation was established (Eq. 1) to relate the IFCC results to the NGSP
results. However, Japan's and Sweden's national standardization pro-
grams establishedmaster equations with different conversion numbers
(please refer to Eqs. 2 and 3) [30].
NGSP %ð Þ ¼ 0:09148 IFCC mmolHbA1c
mmolHb
 
þ 2:512 ð1Þ
JDS JapanDiabetesSociety; in%ð Þ ¼ 0:0927 IFCCþ 1:73 ð2Þ
Mono S Sweden; in%ð Þ ¼ 0:0989 IFCCþ 0:88 ð3Þ
To facilitate the communication of HbA1c analysis, the A1c-Derived
Average Glucose (ADAG) Study Group found a more user-friendly wayto deliver the result from A1C assays in an attempt to obtain better pa-
tient compliance in routine self-monitoring for better diabetesmanage-
ment [34]. By establishing a linear relationship between HbA1c and
average glucose (AG) levels, the ADAG proposed to report HbA1c as
estimated average glucose (eAG, in mg/dL or mmol/L) [34], and the
conversion equation is shown below [33].
eAG
mg
dL
 
¼ 28:7 HbA1c%ð Þ−46:7 ð4Þ
With a true referencemethod developed by the IFCC, global consen-
sus was reached regarding the use of the IFCC reference method for cal-
ibration in clinical laboratories [35]. Three standards were established
based on the presentation of HbA1c results to clinicians, patients, and
scientiﬁc journals. First, in clinical laboratories worldwide, the HbA1c
SI unit will be expressed in IFCC unit (mmol/mol, with no decimals),
and both the IFCC-and NGSP-derived units (%, with one decimal) shall
be reported. Second, the HbA1c conversion table with the IFCC and
NGSP units should be easily accessible to the diabetes community.
Third, journals are recommended to require manuscripts to report
HbA1c in both SI (IFCC) and NGSP units [35]. As a result of global stan-
dardization, countries such as Sweden and Japan, which are famous
for their own HbA1c reference methods, have switched and adapted
these standards. For example, Sweden, which used to utilize its national
referencemethod, namelyMono S, agreed to report HbA1c results using
the IFCC units (mmol/mol) starting in January 2011 [36]. The Japan
Diabetes Society switched to reporting HbA1c results in NGSP(%)
instead of JDS values starting in 2013 [37].
Overall, the effort to standardize HbA1c tests has led to a global con-
sensus on conveying HbA1c results for better diabetes care. Although
the choice of reporting in IFCC, NGSP, or eAGunits still varies by country,
with the recognition of a common language for HbA1c results, the
implementation of HbA1c tests across the globe should not be too far
away.
4. Limitations of HbA1c tests in laboratory settings
In 2001, the IFCCworking group ﬁrst described a higher-order refer-
ence method that was later accepted worldwide as the true reference
method. The IFCC reference method includes the following three
phases: (1) cleavage of hemoglobin by endoproteinase, (2) separation
of the β-chain glycated and non-glycated N-terminal hexapeptides,
and (3) quantiﬁcation by HPLC and electrospray ionization mass spec-
trometry or HPLC and capillary electrophoresis with UV (for a detailed
description, please refer to the IFCC publication) [38]. HbA1c tests can
be categorized into twomain groups: those based on charge differences
(cation exchange matrices and capillary electrophoresis) and structural
differences (afﬁnity chromatography and immunoassays). The HbA1c
tests commonly utilized in laboratory settings typically involve the
pretreatment of blood samples before analysis.
Although glycation is an irreversible reaction, the formation of the
glucose adduct at theN-terminus of theβ chain contributes to addition-
al negative charges in order to allow HbA1c to ﬂow through negatively-
charged cation-exchange matrices [8]. Then, spectrophotometric
analysis of the eluents will provide results as the percentage of each he-
moglobin species in the samples [39]. In general, cation-exchange chro-
matography provides high precision with rapid hemoglobin separation
[32]. With buffer systems at pH 6.2 and below, cation-exchange assays
were found to be sufﬁciently sensitive to quantify αβ dimers, which
may be glycated on both β chains [40]. Although some cation-
exchange HPLC methods are able to indicate the presence of hemoglo-
bin variants, they lack sufﬁcient resolution to recognize speciﬁc glycated
hemoglobin variants. In cases in which the method cannot resolve the
peaks, different HPLC methods have distinct responses. For example,
the Bio-Rad Variant II thalassemia method shows additional peaks as
speciﬁc HbA1c variants [41], whereas other HPLC methods, such as
HA-8140 HPLC, describe hemoglobin variants in a chromatogram as
“variant Hb” [42].
Although most cation-exchange HPLCmethods can now resolve the
most common HbA1c variants and have been widely employed in clin-
ical settings, they are still affected by the high prevalence of hemoglo-
binopathies, particularly in certain ethnicities. Different detection
methods such as afﬁnity separation and immunoassays can then be
used. Afﬁnity chromatography, which reacts boronic acid with the cis-
diol groups of glucose bound to hemoglobin, measures the total
glycated hemoglobin and is therefore considered to be less affected by
the presence of variants. Afﬁnity chromatography assays are more sta-
ble (less affected by pH and temperature) compared with cation-
exchangeHPLC. However, afﬁnity chromatography does not distinguish
amongst the glycated hemoglobin species; thus, they are highly associ-
ated with the overestimation of HbA1c when the total glycated hemo-
globin value is taken as the value of HbA1c [43]. As such, afﬁnity
separation methods commonly give 40–50% higher HbA1c values com-
pared with cation-exchange assays [8]. However, using the newly
established guidelines by NACB (National Academy of Clinical Biochem-
istry), all afﬁnity assays that measure the total glycated hemoglobin
have been calibrated to report theHbA1c equivalents in order to harmo-
nize HbA1c results [16]. In addition, the seemingly non-speciﬁc
boronate afﬁnitymethod can be very useful in cases in which hemoglo-
bin variants are present. In fact, it can be employed as a comparative
method in cases in which cation-exchange HPLC (the DCCT reference
method is Bio-Rex 70 resin cation-exchange HPLC, and NGSP uses the
same referencemethod [31]) yields bizarre chromatograms (“abnormal
separation”, additional peaks, too low HbA1c concentrations or those
above the nondiabetic range) [44].
Immunoassays, particularly immunoturbidity assays, involve an
agglutinator and antibody-coated latex particles. When HbA1c is
present, it reacts with the antibody to inhibit agglutination, hence re-
ducing the turbidity of the sample. However, the pitfall of immunoas-
says is that they are sensitive to HbF interference. For example, a high
concentration of HbF (due to hereditary persistence [11]) has been
shown to cause more than 20% underestimation of the HbA1c values
measured by a DCA 2000 analyzer (a clinically signiﬁcant value) [45].
Although HbA tends to be glycated at the β chain terminal valine, HbF
consists of a γ chain (with glycine at its terminus) and is preferentially
acetylated rather than glycated, which essentially leads to the underes-
timation of glycated hemoglobin in individuals [45]. For a comprehen-
sive discussion of interference in particular methods, please refer to
the table on the NGSP website [46].Table 1
Point-of-care A1c devices.a
Point-of-care instruments
for A1c tests
Manufacturer Types of methods
In2it* Bio-rad, California Afﬁnity separatio
DCA vantage* Siemens Medical Solutions
Diagnostics, New York
Immunoassays/6
Aﬁnion* Axis-Shield, Norway Afﬁnity separatio
Nyocard Axis-Shield, Norway Afﬁnity separatio
GDX/Micromat II* Bio-Rad, California Afﬁnity separatio
Clover Infopia, Korea Afﬁnity separatio
InnovaStar DiaSys, Germany Agglutination/7 m
A1CNow+* Metrika, Bayer, California Immunoassay/5 m
Quo-test Quotient Diagnostics, UK Afﬁnity separatio
a Point-of-care (POC) devices play very signiﬁcant role in aiding the patience compliance of
patients who are not convenient inmoving around for blood testing. POC analyzers which are in
clinical monitoring in order to perform better personalized treatments (*CLIA-waived POC techIn addition to the constant effort to standardize well-established lab
methods to detect HbA1c, attempts to performmore effectivemeasure-
ments of HbA1c in lab settings continue. For example, drop-coating
deposition Raman (DCDR)-spectroscopy has been found to be very
speciﬁc and sensitive for the detection of HbA1c; with a detection
limit approximately 15 fold lower than the lowest physiological concen-
trations associated with clinical settings [47]. Additionally, with the in-
corporation of nanotechnologies, novel systems such as a microﬂuidic
magnetic bead-based immunoassay have been proposed to increase
the accuracy of HbA1c detection [48].
In short, end-users should be aware of possible interference by other
HbA1c variants, particularly if the assays employed can under- or
overestimate HbA1c values in a clinically signiﬁcant way. In addition
to providing a given populationwith the right choice of assays, constant
monitoring of the analytical performance of the assay and quality con-
trol is important. To achieve the goals of intra-laboratory CV b2% and
inter-laboratory CV b3.5%, the bottom line of performance monitoring
and quality control is to perform tests on at least two control materials
with different mean values at the beginning and at the end of the day's
run [16]. In addition to maintaining the standardization efforts for the
NGSP-certiﬁed methods, the development of detection methods that
function based on different principles should be encouraged.
4.1. Point-of-care (POC) technologies: reliability in doubt
Laboratory techniques, such as cation-exchange HPLC and capillary
electrophoresis, are not very useful with regard to the detection of
HbA1c in situ (please refer to Table 1 for a list of available POC ana-
lyzers). The bulky machines and laborious preparations are not a good
match for point-of-care technologies, which are more mobile. Undeni-
ably, with good mobility, POC devices are attractive for nursing practi-
tioners to obtain HbA1c values in situ and thus allow better patient
care. However, the adoption of POC analyzers in clinical settings is
quite controversial due to doubt regarding their accuracy.
There are a variety of commercially available POC tools. However,
only few devices are calibrated precisely enough to gain NGSP certiﬁca-
tion. According to Lenters-Westra, the DCA Vantage (Siemens Medical
Solutions Diagnostics, New York) and Aﬁnion (Axis-Shield, Norway)
are the only devices that are able to meet the NGSP criteria with impre-
cision of b3% CV with two different reagent lots, indicating that their
equivalent analytical performance is equivalent to that obtained with
laboratory-based methods [49]. In general, central laboratory methods
are often subject to positive bias, whereas POC methods tend to exhibit/assay time (min) Detection range and coefﬁcient variants (CV)
n/10 min HbA1c (10 μL whole blood): 4% to 14% (20 mmol/mol to
130 mmol/mol), CV 2.4–3.9% [56]
min HbA1c (1 μL whole blood): 2.5% to 14% (4 mmol/mol to
130 mmol/mol) [57], CV b3% [49]
n/3 min HbA1c (1.5 μL whole blood): 4% to 15% (20 mmol/mol to
140 mmol/mol), CV b3% [58]
n/3 min HbA1c (5 μL whole blood): 4% to 15% (20 mmol/mol to
140 mmol/mol)[58], CV b5% [60]
n/5 min HbA1c (10 μL whole blood): 4% to 15% (20 mmol/mol to
140 mmol/mol), CV 2.93–4.65% [61]
n/5 min HbA1c (4 μL whole blood): 4% to 14% (20 mmol/mol to
130 mmol/mol), CV b3% [62]
in HbA1c: 4% to 15% (20 mmol/mol to 140 mmol/mol),
CV b3% [63]
in Accurate between 7% and 8.5% (53 mmol/mol to
69 mmol/mol) [55]
n/4 min HbA1c: 4% to 15% (20 mmol/mol to 140 mmol/mol),
CV b3% [64]
self-monitoring and also allow the practitioners to perform routine checking in situ on
par with laboratory machineries in HbA1c testing provide amore practical way for better
nologies [53]).
Table 2
HbA1c biosensors.a
Compound detected Characteristics Types of biosensors Detection range/limits Sensitivity Limitations
Fructrosyl valine (FV) -Detect: End product from decomposition
of glycated hexapeptides
-Biological recognition element: Enzyme
fructosyl amine oxidase (FAO)
Electrochemical (amperometric)
with magnetic nanoparticles
-Detection range: 0 to 2 mM FV
-Detection limit: 0.1 mM for FV
(Chawla et al., 2011) [74]
Not available -Lack of reproducibility and
stability
Electrochemical (amperometric) with
zinc oxide nanoparticles–polypyrrole
ﬁlm
-Detection range: 0.1 to 3 mM FV
-Detection limit: 50 uM FV
(Chawla et al., 2012) [73]
38.42 μA/mM
Disposable iridium-modiﬁed
electrochemical biosensor
(amperometric)
-Detection range: 0 to 2 mM of FV
-Detection limit: Not available
(Fang et al., 2008) [72]
21.5 μA/mM cm2
Glycated hemoglobin
(HbA1c)
-Detect: HbA1c
-Biological recognition element:
Anti-HbA1c antibody
Electrochemical (potentiometric)
immunosensors with
mixed SAMs wrapped nano-spheres
array
-Detection range: 50 to 170.5 ng/mL
HbA1c
-Detection limit: Not available
(Xue et al., 2010) [67]
94.73 μV/(ng/mL) -Reproducibility is of concern
-Detect: Fc-IgG-HbA1c immunocomplexes
-Biological recognition element:
anti-HbA1c antibody
On-chip electrochemical ﬂow
immunoassay
-Detection range: up to 500 μg/mL
-Detection limit: Not available
(Tanaka et al., 2007) [75]
Not available -Laborious pretreatment
-Detect: HbA1c
-Biological recognition element:
Anti-HbA1c antibody
Sandwich immunoassays on
polydimethylsiloxane-based
antibody microarrays
-Detection range: 10–100 ng/mL
-Detection limit: 3.58 ng/mL
(Chen et al., 2012) [68]
4–5 orders of magnitude higher -Long incubation time (2 h)
Boronic acid-based HbA1c Biosensors
Detect: HbA1c
-Biological recognition element:
Ferroceneboronic acid
Electrochemical (piezosensor)
immunoassay
-Detection range: 0 to 20%
-Detection limit: N5%
(standard deviation 20%)
(Halamek et al., 2007) [76]
Not available -Low sensitivity
-Low speciﬁcity
-Detect: HbA1c
-Biological recognition element:
Ferroceneboronic-acid labeled
anti-HbA1c antibody
Electrochemical (piezosensor)
immunoassay
-Detection range: 4 to 13%
-Detection limit: Not available
(Halamek et al., 2007) [66]
Sensitivity was increased at
three fold compared to without
antibodies (Halamek et al., 2007)
-Low sensitivity
-Detect: Wide range of glycoproteins,
for example HbA1c
-Biological recognition element:
Boronic-acid
Disposable biochip Not available (Son et al., 2006) [77] Not available -Laborious pretreatment on
sample matrix.
-High sample volume was
required (50 μL)
-Detect: Wide range of glycoproteins,
for example HbA1c
-Biological recognition element: Boronic-acid
-Coupled with GOx (glucose oxidase)
backﬁlling assay
Electrochemical -Detection range: 2.5 to 15% HbA1c
-Detection limit: Not available
(Song et al., 2009) [70]
Not available -Lack of speciﬁcity to HbA1c
-Detect: Glycoproteins
-Biological recognition element: Self-assembled
monolayer (SAM) thiophene-3-boronic acid
Afﬁnity biosensors with impedance
measurement
-Detection range: 1 to 100 ng/μL
-Detection limit: 1 ng/μL of HbA1c
(Hsieh et al., 2013) [71]
Not available -Lack of stability
-Detect: HbA1c
-Biological recognition element:
phenylboronic acid
SPR (surface plasmon resonance)
biosensor
-Detection range:0.43 to 3.49 μg/mL
-Detection limit: 0.01 μg/mL
(Liu et al., 2008) [69]
Not available -Expensive instrumentation
a The table shows examples of fabricated HbA1c biosensors. HbA1c biosensors can be grouped under twomain groups: the Fructrosyl valine (FV) and HbA1c biosensors. The FV biosensorsmeasure the end product from the decomposition of glycated
hexapeptides (after proteolysis of HbA1c), while the HbA1c biosensorsmeasure concentrations of HbA1c directly. TheHbA1c biosensors typically involve immunoglobulins as the biological recognition elements, and some of themutilize the biomimetic
ability of boronic acid to selectively measure HbA1c.
negative bias. Hence, the relative biases of POC and CL (central lab)
methods are potentially unacceptable in cases in which different
principle-basedmethods are employed interchangeably [50]. Using dif-
ferentmethods can lead to complicated data analysis issues, but the 18%
false negatives obtained by HbA1c POC devices, which can lead to high
incidence of missed diagnosis of diabetes, is a concern [51].
In addition to inconsistent performance, clinical doubt regarding the
HbA1c values obtained using POC devices has obstructed the wide ap-
plication of POC devices in clinical settings. POC devices are susceptible
to reagent variations across different batches [52]. POC devices are often
perceived to not be on par with standard laboratory tests in performing
HbA1c measurements. Due to the unstable analytical performance of
some POC analyzers, clinical practices are advised to always compare
the POC methods to the laboratory methods before adopting POC
methods in routine practice [51]. Although the18% false negative results
obtained using POC devices remain a pressing issue, the potential of the
POC devices for incorporation in clinical practice should not be
overlooked. Therefore, more attention should be given to the ongoing
effort to increase the accuracy and decrease the variability between
batches of commercialized POC methods. Hence, the waived status of
the assessment of POCmethods by the Clinical Laboratory Improvement
Amendments (CLIA) causes concern that the quality of POC methods
may be compromised.
Clinical Laboratory Improvement Amendments was established in
1988 to ensure the accuracy and reliability of a method regardless of
the places where the test is performed [53]. Under the law, waived
tests are deﬁned as laboratory examinations cleared by the Food and
Drug Administration (FDA) and safe for household use [53]. With
CLIA-waived status, POC devices are not required to undergo assess-
ment under other schemes, such as CAP surveys (refer to Section 3 for
discussion). Thus, the concern is that the analytical performance consis-
tency of POC devices is not known, rendering diabetes care in the gen-
eral population less effective. As of today, the ADA (American Diabetes
Association) has excluded the use of POC analyzers for the diagnosis
of diabetes due to the variability in analytical performance.
With advances of technology, the analytical performance of POC de-
vices can be improved, andwith the revised CLIA-waived status creating
the obligation to participate in external quality control schemes, POC
devices have huge potential to become reliable diagnosis tools in the
near future. However, because the therapeuticmodality is often decided
by HbA1c values, the negative bias of POC analyzers could affect clinical
decisions. Therefore, pharmacists and medical practitioners should be
cautious in relying solely on POCs. Even if most CLIA-waived POC de-
vices exhibit a satisfactory correlation to laboratory methods, it is
often advisable to perform a POC test and a laboratory test to avoidmis-
judgments in practice. Again, it may take some time before POC devices
are ready for diabetic diagnosis purposes; however, for diabetic care and
management purposes, POC devices are reliable [54] and more cost-
effective [55] and yield a higher patient-satisfaction level, due to the
decentralized system to provide rapid and same-visit results.
4.2. New ideas for HbA1c tests: glycated hemoglobin biosensors
Unlike other methods, HbA1c biosensors always involve a layer of
biological recognition elements that create speciﬁcity and selectivity to-
wards HbA1c. Because the designs of HbA1c biosensors often involve
miniaturized set-ups, it is fair to anticipate a revolution of accurate
and cost-effective HbA1c biosensors in POC instruments in clinical
settings.
The main group of HbA1c biosensors are those designed to detect
HbA1c directly, and they can be categorized as amperometric, potentio-
metric, piezoelectric biosensors, and biochips [56]. Electrochemical bio-
sensors that detect HbA1c directly typically involve an anti-HbA1c
antibody as the biological recognition element and are commonly
known as immunosensors. For example, by combining the principle of
piezoelectricity and electrochemistry, Halámek et al. developed anHbA1c immunosensor using an antibody labeled in situ with
ferroceneboronic acid (redox label) to amplify the electrochemical sig-
nal [57]. Utilizing nanotechnology, Xue et al. reported a miniaturized
potentiometric HbA1c immunosensor based on mixed SAM (Self As-
sembled Monolayer)-wrapped nanospheres. The prototype was then
tested for its consistency in a clinical setting to determine the potential
of HbA1c biosensors in POC instruments [58]. Due to a constant urge to
increase the sensitivity and speciﬁcity of HbA1c biosensors, a sandwich
immunoassay was proposed to detect HbA1c at the nanomolar level at
high speciﬁcity [59]. Expensive instrumentation, such as SPR (surface
plasmon resonance) spectroscopy, has also been utilized to fabricate
HbA1c biosensors for the robust detection of HbA1c with high sensitiv-
ity [60]. When conducting detection with high sensitivity, it would be
wise to be cautious if the techniques utilized can compromise the rapid-
ity of the results generated.
Boronic acid, typically used in afﬁnity chromatography, is an excel-
lent biomimetic molecule that is highly utilized as the biological recog-
nition element in HbA1c biosensors to selectively bind to the sugar
moiety of HbA1c. For example, Song and Yoon manipulated a boronic
acid-modiﬁed electrode with a GOx (glucose oxidase) backﬁlling assay
to quantitatively measure HbA1c [61]. Utilizing the biomimetic nature
of boronic acid, Hsieh et al. also fabricated an afﬁnity biosensor to mea-
sure HbA1c concentrations based on impedance [62]. Using a low-cost
and low-volume sample, it was claimed to be feasible to develop the
proposed HbA1c biosensor prototype into a sensitive point-of-care
device [62]. However, because boronic acid binds to the cis-diol of any
glycan moiety (HbA1c is only one of the glycan moieties), studies
attempting to fabricate HbA1c biosensors should be cautious to not
compromise speciﬁcity by using the cost-effective boronic acid in
place of antibodies.
Fructosyl valine (FV), which is generated by the decomposition of
glycated hexapeptides (the product of HbA1c proteolysis) has also
been highly exploited in the development of HbA1c biosensors. By ma-
nipulating the enzyme fructosyl amine oxidase (FAO) as the biological
recognition element, FV can be further catalyzed to produce hydrogen
peroxide for electrochemical detection. Because FAO can be extracted
from different organisms (marine yeast or bacteria such as Escherichia
coli and Arthrobacter sp.), the fabrication of FV biosensors is constantly
challenged by altered enzymatic activity, the sensitivity and reproduc-
ibility of the biosensors, and the operational potential and temperature
[63]. To counter the weaknesses of FV biosensors, Fang et al. designed a
disposable iridium-modiﬁed FV biosensor to detect HbA1c [63]. By in-
corporating nanotechnology in the fabrication of the FV biosensor,
Chawla and Pundir managed to develop an amperometric biosensor
for HbA1c with improved operational efﬁciency, higher stability and
increased sensitivity [64]. For examples of different types of HbA1c bio-
sensors and their analytical performance, please refer to Table 2.
In summary, the attempt to develop HbA1 biosensors is a positive
effort to stimulate innovations for the creation of better point-of-care
analyzers in the future. Although the stability of biomolecules as the
recognition element has always been a concern in the reliability of de-
tection, with the advancement of nanotechnology, more effective and
consistent biosensors that can be as accurate as current lab HbA1c
tests can now be developed.
5. Prediabetes in predicting incident diabetes: is HbA1c an effective
screening tool?
Before one becomes hyperglycemic, one can be asymptomatic and
remain dysglycemic for years. Dysglycemia occurs when the blood glu-
cose level is higher than the normal level but does not reach the diabetic
cutoff. In fact, the prediabetic stage is considered part of the continuum
of dysglycemia. Prediabetes refers to IFG (impaired fasting glucose with
FPG at 100–125 mg dL−1 or 5.6–6.9 mmol/L), IGT (impaired glucose
tolerance with 2-hour oral glucose test at 140–199 mg dL−1 or 7.8–
11.0 mmol/L) or an A1c of 5.7 to 6.4% (ADA, American Diabetes
Association prediabetes diagnostic range) [23]. Because type 2 diabetes
is a progressive disease, in cases in which patients are asymptomatic,
delayed intervention and therapy can lead to morbidities and prema-
ture death. In fact, studies have shown that prediabetic patients are as-
sociated with a 20% increase in cardiovascular diseases, with higher
prevalence of neuropathy, chronic kidney disease and microvascular
complications [65]. The Diabetes Prevention Project revealed that only
4.8% of individuals are properly diagnosed as prediabetic, and the ma-
jority of patients remain undiagnosed [66], reﬂecting the urgent need
for an effective screening tool to recognize high-risk populations.
Because the HbA1c cutoff sensitivity depends on demography,
ethnicity, age, and the detection methods chosen in a particular health
system, it is not surprising that different countries may have variable
values for prediabetes. For example, instead of utilizing the ADA
cutoff, the CDA (Canadian Diabetes Association) has chosen 6.0 to 6.4%
(42–46 mmol/mol) to deﬁne prediabetes [67]. To deﬁne prediabetic
ranges with the HbA1c levels, Suzuki et al. performed a ROC (Receiver
Operating Characteristic) curve analysis to reveal that A1C ≥5.7% is
better than A1C ≥6.0% as the cut-off point to screen for prediabetes in
Japanese patients [68].
However, compared to its counterparts, HbA1c appears to have
lower screening power for prediabetes. In non-Hispanic white society,
utilizing the ADA HbA1c prediabetic criterion, Lorenzo et al. found that
the HbA1c test is less sensitive than the FPG and OGTT tests [69]. Coin-
ciding with Lorenzo et al.'s ﬁndings, Zhou et al. also concluded that FPG
performs better as a screening tool than theHbA1c test based on studies
in Qingdao, China [70]. In contrast, a Bulgarian population-based study
found a signiﬁcant positive correlation between HbA1c and both the
fasting plasma glucose test and OGTT by setting the HbA1c cutoff at
≥5.5% [71], indicating that the HbA1c test can be an equally effective
screening tool. In fact, in an attempt to analyze the screening power of
HbA1c, a review of 63 studies concluded that the HbA1c test is as effec-
tive as FPG as a screening tool [21]. More recently, in clinical practice,
the HbA1c test was recognized to be equally good, and often better, as
a screening tool comparedwith FPG [72]. Although the evidence is inad-
equate, HbA1c was recently found to have similar screening power as
OGTT [72]. To enhance the screening power, Heianza et al. suggested
that the use of both the HbA1c and FPG tests will allow more efﬁcient
recognition of individuals who are most likely to develop diabetes [27].
In short, the HbA1c test can be an effective screening tool for predi-
abetic individuals when the cutoffs are adjusted based on ethnicity, de-
mography, gender, and age. To accurately screen for prediabetes,
additional plasma glucose tests (namely the FPG and OGTT tests) are
still necessary [73]. With the early detection of prediabetes, individuals
can receive early intervention, efﬁciently preventing the progression to
type 2 diabetes. Although the implementation of HbA1c as the sole
screening tool remains premature, through the constant surveying
and standardization of HbA1c methods using adjusted cutoffs, the
HbA1c test has high potential to become a reliable independent screen-
ing tool for the detection of prediabetes and undiagnosed diabetes.
6. Glycated hemoglobin in the treatment and long-term
management of diabetes
Given the impacts of T2DM on society, it is important to seek out the
most suitable treatments to delay the progression of diabetes. There are
a plethora of treatments available that cater to different groups of predi-
abetic or diabetic patients, including monotherapy with hypoglycemic
drugs, combinations of drugs, insulin therapy and lifestyle changes,
each of which can be initiated based on the glycemic status and patient
age, pre-existing medical complications, and/or diabetic symptoms. To
initiate treatment, clinicians could refer to the glycemic status reﬂected
by HbA1c tests.
To strike a balance between side effects and effectiveness of delaying
the progress of the disease, it is very important to personalize therapy
for each T2DM patient. For example, metformin is as effective as life-style modiﬁcation in individuals aged 24 to 44 years old or in those
with BMI ≥35 kg/m2, but these categories include only a small group
of diabetic patients [74]. In reality, clinicians may be hesitant to treat
patients aggressively, due to fear of hypoglycemic complications or un-
easiness associated with adapting to a new therapy. The rule of “ABC”
(A1C, Blood Pressure, Cholesterol) outlines the treatment goals for A1c
(b7%, submit to modiﬁcation based on individuals' adverse effects
during glycemic management), blood pressure (≤129/79 mm Hg),
and cholesterol (LDL b100 mg/dL in patients with ≥40 years of vascu-
lar disease) [75].
Although the role of the HbA1c test has long been recognized in the
management of the treatment of T2DM, different organizations around
the world have suggested different treatment goals for mitigating the
cases of over- and under-treatment. For example, the ADA (USA) sug-
gested a treatment goal of HbA1c b7%, whereas the JDS (Japan) aims
to achieve 6.5% for a successful diabetes treatment [76].
Because the rules for glycemic control and treatment goals have al-
ways included HbA1c values for practical clinical decision on appropri-
atemodalities, it is important for different countries and regions to have
speciﬁc treatment goals for the HbA1c level in order to achieve more
personalized and effective treatment.
7. Conclusions
Although there used to bemany debates regarding the utilization of
HbA1c tests to diagnose type 2 diabetesmellitus, it has now been recog-
nized as reliable diagnostic biomarkers for type 2 diabetes. An IUPAC
unit (IFCC unit, mmol/mol) for HbA1c has been established, and to
standardize all of the methods, commercial methods are required to
maintain traceability to IFCC reference methods. Although laboratory
HbA1c methods have been utilized to perform HbA1c measurements,
the need for bulky machines can decrease patients' compliance, thus
affecting the effectiveness of diabetes management. However, due to
biases associated with POC analyzers, clinical practitioners are hesitant
to rely on POC analyzers as a stand-alone HbA1c method. To populate
the use of point-of-care (POC) HbA1c analyzers in clinical settings,
more efforts to create sensitive miniaturized HbA1c biosensors should
be encouraged. Although the development of accurate POC devices is
of utmost importance, future HbA1c tests should also consider cost
and ease of interpretation in common households. Because type 2 dia-
betes is a progressive disease, effective screening of prediabetes is
very important to reducing the cases of undiagnosed diabetes and to
thus perform early treatment and management of the glycemic status.
8. Future perspectives
Although the traditional role of HbA1c in diabetes management has
long been accepted, its contribution to the diagnosis of type 2 diabetes is
only slowly gaining acceptance. With the current efforts directed at
standardization, the authors predict that HbA1c testswill be used for di-
abetes diagnosis across the globe. The development of more consistent
and accurate HbA1c methods remains an ongoing effort to maintain
traceability to important diabetes studies. However, to improve the
performance of POC analyzers, constant surveillance of batch-to-batch
variation is necessary. By controlling the quality and maintaining the
performance of different lots of POC devices, end users can gain conﬁ-
dence in utilizing POC devices for better diabetes management. With
an assurance of quality, the employment of POC analyzers in clinical set-
tings is anticipated. The quality control for CLIA-waived POC analyzers is
very critical, because they can be very beneﬁcial to diabetes manage-
ment in developing countries that do not have sufﬁcient health
budget allocations to perform HbA1c laboratory tests nationwide. Ac-
cording to one survey, the set-up costs for the laboratory HbA1c test
are 13.6 fold greater than those for the plasma glucose measurement
[77], and POC analyzers that are on par with laboratory methods can
be cost-effective and convenient, particularly in underserved regions.
With the effort to standardize the test and the advancement of technol-
ogy, it is only a matter of time for themobile analyzers to be recognized
as effective and accurate tools for the diagnosis and management of di-
abetes in situ. HbA1c biosensor development should be encouraged to
produce more efﬁcient miniaturized devices that may be potentially
useful POC analyzers. To tackle the implementation cost for HbA1c
tests, attention should be paid to the use of cost-effective materials
while fabricating HbA1c biosensors. HbA1c tests have the potential to
be more convenient, user-friendly, accurate, and cost-effective in
order to aid world-wide diabetes care.
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